A revolutionary regenerative therapy for management of chronic inflammatory diseases based on neonatal Mesenchymal Stem Cells

Informacje na temat projektu

NeoCellBank

Identyfikator umowy o grant: 864301

DOI

10.3030/864301

Projekt został zamknięty

Data podpisania przez KE 29 Kwietnia 2019

Data rozpoczęcia 1 Maja 2019

Data zakończenia 31 Sierpnia 2019

Finansowanie w ramach

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Koszt całkowity

€ 71 429,00

Wkład UE

€ 50 000,00

Koordynowany przez

VETBIOBANK SAS
France

Periodic Reporting for period 1 - NeoCellBank (A revolutionary regenerative therapy for management of chronic inflammatory diseases based on neonatal Mesenchymal Stem Cells)

Okres sprawozdawczy: 2019-05-01 do 2019-08-31

Podsumowanie kontekstu i ogólnych celów projektu

At Vetbiobank we verified the feasibility of NeoCellBank project to optimize our disruptive cell therapy biomanufacturing platform and release it into market. While we already demonstrated in a Proof of Concept study, long term safety and efficacy of our top-tier candidate, Canipren®-Joint to treat canine osteoarthritis, we plan to improve our manufacturing capability and technology transfer, prior to clinical validation. We assessed all the investment required to complete the project, for which we will pursue financing support of circa €2.5M from the EC scheme of Accelerator project. We have evaluated the potential of NeoCellBank to generate >€13M profit and new employment (+15 new job positions). We have already received proofs of interest from our key stakeholders: 3 public research centers, vet clinical investigators located in France and private pharma and biotech companies; we have already established a partnership to secure our European distribution channels with one top 10 vet pharma company. We concluded to continue with NeoCellBank project, motivated by the confirmation of the uniqueness and competitiveness of our innovation with this feasibility study.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

TECHNICAL FEASIBILITY, including: technology definition and transfer; Canipren®-Joint specification; analysis of validation procedures; detailed technical plan to increase TRL to 8; analysis of risks and design of a mitigation and contingency plan.
COMMERCIAL FEASIBILITY, including: market analysis; end-user´s segmentation; main competitors; definition of commercial strategy; SoA and FtO analysis; business model; commercialization and dissemination plan, including IPR strategy.
FINANCIAL FEASIBILITY, including: in-depth cost analysis to evaluate our capacity to take the innovation; business projections for the first five years after NeoCellBank market launch in a conservative sales scenario.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

NeoCellBank will be the first biomanufacturing platform able to yield neonatal MSC-based therapies from placental tissues for vet and human medicinal applications, improving the benefits (higher standardized treatment, higher cell proliferation capacity, and lower immunogenicity, among others) and avoiding ethical constrains usually associated to adult cells, and accelerating cell therapy development process in terms of cost, regulations and time-to-market. It will allow us to grow reaching >€36M revenue and +15 new employees after the 5th year of commercialization.

image.png